You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

Citation Tools

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Lai AY, Sorrentino JA, Dragnev KH, et al
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
Journal for ImmunoTherapy of Cancer 2020;8:e000847. doi: 10.1136/jitc-2020-000847